Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 18/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 12/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD1 | P21728 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2795110 | 1.00 | ADRB2 (0.47) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL18993729 | 0.91 | ADRB2 (0.49) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL1973360 | 0.89 | ADRB2 (0.46) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL18993739 | 0.89 | ADRB2 (0.46) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL30490482 | 0.89 | ADRB2 (0.46) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL99134 | 0.89 | ADRB2 (0.46) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL5179147 | 0.89 | ADRB2 (0.46) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL18946383 | 0.89 | ADRB2 (0.48) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL2568651 | 0.89 | ADRB2 (0.46) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL865904 | 0.89 | ADRB2 (0.46) | ADRB2ADRB1DRD2DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022172292-A1 | A PROCESS FOR PREPARING ABEDITEROL AND INTERMEDIATES THEREOF | GBR LABORATORIES PRIVATE LIMITED (IN) | 2022-08-18 | — | — | WO | disclosed |
| EP-3138837-B1 | INDACATEROL FREE BASE IN SOLID FORM | CRYSTAL PHARMA SAU (ES) | 2021-11-24 | — | — | EP | disclosed |
| EP-3848354-A1 | PROCESS FOR THE PREPARATION OF INDACATEROL AND INTERMEDIATES THEREOF | Crystal Pharma, S.A.U. (ES) | 2021-07-14 | — | — | EP | disclosed |
| EP-2897937-B1 | PROCESS FOR THE PREPARATION OF INDACATEROL AND INTERMEDIATES THEREOF | CRYSTAL PHARMA SAU (ES) | 2017-12-06 | — | — | EP | disclosed |
| EP-3138837-A1 | INDACATEROL FREE BASE IN SOLID FORM | Crystal Pharma, S.A.U. (ES) | 2017-03-08 | — | — | EP | disclosed |
| US-20150210643-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. | 2015-07-30 | — | — | US | disclosed |
| US-20110028442-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2011-02-03 | — | — | US | disclosed |
| EP-2254860-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2010-12-01 | — | — | EP | disclosed |
| EP-2057122-B1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE 2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2010-09-01 | — | — | EP | disclosed |
| US-20100168161-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-07-01 | — | — | US | disclosed |
| US-7745462-B2 | Quinoline-2-one derivatives for the treatment of airways diseases | NOVARTIS AG (CH) | 2010-06-29 | — | — | US | disclosed |
| WO-2009106351-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2009-09-03 | — | — | WO | disclosed |
| US-20070066607-A1 | Quinoline-2-one derivatives for the treatment of airways diseases | NOVARTIS AG (CH) | 2007-03-22 | — | — | US | disclosed |
| CN-1280259-C | Arylanilines beta-2 adrenergic receptor agonists | THERAVANCE INC (US) | 2006-10-18 | — | — | CN | disclosed |
| CN-1585742-A | Arylanilines beta-2 adrenergic receptor agonists | THERAVANCE INC (US) | 2005-02-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168161-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885DRD2 246/4885 |
| US-20070066607-A1 | Quinoline-2-one derivatives for the treatment of airways diseases | ADRB2, ADRA2C, ADRB1 | ADRB2 1/4885ADRB1 3/4885DRD2 634/4885 |
| US-20150210643-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885DRD2 246/4885 |
| US-20110028442-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885DRD2 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.